NCT04094077: Evaluating AGuIX Nanoparticles in Combination With Stereotactic Radiation for Brain Metastases

NCT04094077
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Ph+ase 2
Drug Category: 

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients with prior local treatment with radiotherapy (whole/partial brain or stereotactic radiosurgery) or surgical resection of brain lesions
https://ClinicalTrials.gov/show/NCT04094077

Comments are closed.

Up ↑